265 related articles for article (PubMed ID: 30190154)
1. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
5. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
6. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
8. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
9. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey.
Solomon DH; Yelin E; Katz JN; Lu B; Shaykevich T; Ayanian JZ
Arthritis Res Ther; 2013 Mar; 15(2):R43. PubMed ID: 23506671
[TBL] [Abstract][Full Text] [Related]
12. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt.
Polinski JM; Brookhart MA; Ayanian JZ; Katz JN; Kim SC; Lii J; Tonner C; Yelin E; Solomon DH
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1634-43. PubMed ID: 24664991
[TBL] [Abstract][Full Text] [Related]
13. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
[TBL] [Abstract][Full Text] [Related]
15. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort.
Moura CS; Schieir O; Valois MF; Thorne C; Bartlett SJ; Pope JE; Hitchon CA; Boire G; Haraoui B; Hazlewood GS; Keystone EC; Tin D; Bykerk VP; Bernatsky S;
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1104-1111. PubMed ID: 31112011
[TBL] [Abstract][Full Text] [Related]
16. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
Yazdany J; Tonner C; Schmajuk G; Lin GA; Trivedi AN
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1447-55. PubMed ID: 25244314
[TBL] [Abstract][Full Text] [Related]
17. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys.
Ward MM
J Rheumatol; 1999 Mar; 26(3):546-50. PubMed ID: 10090160
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
20. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]